Chemotherapy-Induced Peripheral Neuropathy (CIPN) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report

Chemotherapy-induced peripheral neuropathy (CIPN) stands out as a prevalent adverse effect triggered by antineoplastic medications, with its occurrence ranging from 19% to over 85%. It primarily manifests as sensory nerve damage, accompanied by varying degrees and durations of motor and autonomic alterations. Given its high occurrence among cancer patients, CIPN poses a significant challenge for patients, survivors, and their healthcare providers. This is primarily due to the absence of a single effective method to prevent CIPN. Central sensitization is pivotal in neuropathic pain, especially from nerve damage. The harm to peripheral nerves, particularly C-fibers, results in spontaneous activity that disrupts secondary neurons in the spinal dorsal horn, leading to heightened excitability due to various molecular changes. Clinically, CIPN manifests as sensory, motor, and autonomic deficits of varying severity. Sensory symptoms usually initiate the condition, typically affecting the hands and feet and resembling a classic “glove and stocking” neuropathy, with the most distal parts of the limbs exhibiting the most pronounced deficits. These symptoms encompass numbness, tingling, altered touch sensation, impaired vibration perception, paresthesias, and discomfort triggered by contact with warm or cold surfaces. Several predisposing risk factors for CIPN have been identified, including patient age (higher risk in older individuals), pre-existing neuropathy before chemotherapy (e.g., diabetic neuropathy), a history of smoking, impaired kidney function with reduced creatinine clearance, exposure to other neurotoxic chemotherapy agents, the presence of paraneoplastic antibodies, and direct neuropathy associated with the cancer itself.
• The prevalence of CIPN varies depending on the chemotherapy agent used, with reported rates ranging from 19% to more than 85%. It is most prominent in the case of platinum-based drugs (70–100%), taxanes (11–87%), thalidomide and its derivatives (20–60%), and ixabepilone (60–65%).
• According to Thelansis, the incidence of chemotherapy-induced peripheral neuropathy (CIPN) in the G8 countries is estimated to range from 3.2 million cases in 2020 to 3.5 million by 2030.

Thelansis’s “Chemotherapy-Induced Peripheral Neuropathy (CIPN) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033″ covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Chemotherapy-Induced Peripheral Neuropathy (CIPN) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

KOLs insights of Chemotherapy-Induced Peripheral Neuropathy (CIPN) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.
Chemotherapy-Induced Peripheral Neuropathy (CIPN) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.
Read more: Chemotherapy-Induced Peripheral Neuropathy (CIPN) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033
Tags: Chemotherapy-Induced Peripheral Neuropathy (CIPN), Chemotherapy-Induced Peripheral Neuropathy (CIPN) market outlook, Chemotherapy-Induced Peripheral Neuropathy (CIPN) competitive landscape, Chemotherapy-Induced Peripheral Neuropathy (CIPN) market forecast, Thelansis, Primary market research, KOL insights, Competitive Intelligence (CI)